1246745-48-1

Upstream product

• 302840-63-7 (1R)-[1-(3,5-dichloro-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 
• 626-43-7 3,5-Dichloroaniline 
• 50824-05-0 4-trifluoromethoxybenzyl bromide 
• 341027-25-6 (2R,5R)-3-(3,5-dichlorophenyl)-2-isopropyl-5-methyl-1-(2,2,2-trichloroacetyl)-imidazolidin-4-one 

Downstream Products

• 688756-00-5 (S)-2-[(R)-7-(3,5-dichlorophenyl)-5-methyl-6-oxo-5-(4-trifluoromethoxybenzyl)-6,7-dihydro-5H-imidazo[1,2-a]imidazol-3-ylsulfonylamino]propionamide 
• 688756-19-6 (R)-7-(3,5-dichloro-phenyl)-5-methyl-6-oxo-5-(4-trifluoromethoxy-benzyl)-6,7-dihydro-5H-imidazo[1, 2-a]imidazole-3-sulfonyl chloride 
• 1246745-49-2 C₂₂H₂₂Cl₂F₃N₃O₄ 
• 1246745-49-2 C₂₂H₂₂Cl₂F₃N₃O₄ 
• 944580-11-4 (R)-N-(3,5-dichlorophenyl)-2-[3-(2,2-dimethoxyethyl)ureido]-2-methyl-3-(4-trifluoromethoxyphenyl)propionamide 
• 688756-17-4 (R)-1-(3,5-dichloro-phenyl)-3-methyl-3-(4-trifluoromethoxy-benzyl)-1H-imidazo[1,2-a]-imidazol-2-one 
• 1175561-69-9 (R)-2-amino-3-(4-trifluoromethoxyphenyl)-N-(3,5-dichlorophenyl)-2-methylpropionamide p-toluenesulfonic acid salt 
• 1246745-52-7 (R)-3-(3,5-dichlorophenyl)-5-methyl-5-(4-trifluoromethoxybenzyl)imidazolidine-2,4-dione 
• 688756-15-2 (R)-2-amino-3-(4-trifluoromethoxyphenyl)-N-(3,5-dichlorophenyl)-2-methylpropionamide 

Relevant academic research and scientific papers

Efficient synthesis of a small molecule, nonpeptide inhibitor of LFA-1

Figure Presented. A three-stage process for the synthesis of LFA-1 inhibitor 1 from amine 4 with an overall yield of 65% is described. The key stage involves a Ph3PCl2-induced dehydration/cyclization of urea 6 followed by a regiosele

Synthesis of 6,7-Dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is an improved multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins

Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides

Disclosed is a multi-step process for preparing a compound of Formula I: wherein R1 to R3 are as defined herein. The compounds of formula I inhibit the binding of human intercellular adhesion molecules to the Leukointegrins. As a res